# KORU Medical Systems, Inc.: financial statements, quarterly

KRMD · Nasdaq · CIK 704440 · [Healthcare](/sectors/healthcare.md) · fiscal year ends Dec 31

Pages: [Overview](/companies/krmd.md) · [Financials](/companies/krmd/financials.md) · [Filings](/companies/krmd/filings.md) · [Insiders](/companies/krmd/insiders.md)

Standardized line items from XBRL company facts. Each value links to its filing; d marks a value derived from year-to-date figures. Other view: [annual](/companies/krmd/financials.md?period=annual).

## Income statement

| Line item | Unit | Q3 FY2023 (2023-09-30) | Q4 FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Revenue | $m | [7.0](/filings/0001161697-24-000441.md) | [7.2 d](/filings/0001161697-25-000103.md) | [8.2](/filings/0001161697-25-000169.md) | [8.4](/filings/0001161697-25-000217.md) | [8.2](/filings/0001161697-25-000372.md) | [8.8 d](/filings/0001161697-26-000052.md) | [9.6](/filings/0001161697-26-000108.md) | [10.2](/filings/0001161697-26-000189.md) | [10.4](/filings/0001161697-25-000372.md) | [10.9 d](/filings/0001161697-26-000052.md) | [11.8](/filings/0001161697-26-000108.md) | [12.0](/filings/0001161697-26-000189.md) |
| Cost of revenue | $m | [2.7](/filings/0001161697-24-000441.md) | [2.9 d](/filings/0001161697-25-000103.md) | [3.1](/filings/0001161697-25-000169.md) | [3.0](/filings/0001161697-25-000217.md) | [3.0](/filings/0001161697-25-000372.md) | [3.3 d](/filings/0001161697-26-000052.md) | [3.6](/filings/0001161697-26-000108.md) | [3.7](/filings/0001161697-26-000189.md) | [4.1](/filings/0001161697-25-000372.md) | [4.1 d](/filings/0001161697-26-000052.md) | [4.5](/filings/0001161697-26-000108.md) | [4.2](/filings/0001161697-26-000189.md) |
| Gross profit | $m | [4.3](/filings/0001161697-24-000441.md) | [4.3 d](/filings/0001161697-25-000103.md) | [5.1](/filings/0001161697-25-000169.md) | [5.5](/filings/0001161697-25-000217.md) | [5.2](/filings/0001161697-25-000372.md) | [5.6 d](/filings/0001161697-26-000052.md) | [6.0](/filings/0001161697-26-000108.md) | [6.5](/filings/0001161697-26-000189.md) | [6.3](/filings/0001161697-25-000372.md) | [6.8 d](/filings/0001161697-26-000052.md) | [7.2](/filings/0001161697-26-000108.md) | [7.8](/filings/0001161697-26-000189.md) |
| Research and development | $m | [1.3](/filings/0001161697-24-000441.md) | [1.3 d](/filings/0001161697-25-000103.md) | [1.5](/filings/0001161697-25-000169.md) | [1.1](/filings/0001161697-25-000217.md) | [1.5](/filings/0001161697-25-000372.md) | [1.1 d](/filings/0001161697-26-000052.md) | [1.1](/filings/0001161697-26-000108.md) | [1.2](/filings/0001161697-26-000189.md) | [0.9](/filings/0001161697-25-000372.md) | [1.1 d](/filings/0001161697-26-000052.md) | [1.3](/filings/0001161697-26-000108.md) | [1.1](/filings/0001161697-26-000189.md) |
| Selling, general and administrative | $m | [4.6](/filings/0001161697-24-000441.md) | [5.0 d](/filings/0001161697-25-000103.md) | [5.4](/filings/0001161697-25-000169.md) | [5.3](/filings/0001161697-25-000217.md) | [5.1](/filings/0001161697-25-000372.md) | [5.8 d](/filings/0001161697-26-000052.md) | [6.0](/filings/0001161697-26-000108.md) | [5.4](/filings/0001161697-26-000189.md) | [6.0](/filings/0001161697-25-000372.md) | [6.0 d](/filings/0001161697-26-000052.md) | [6.6](/filings/0001161697-26-000108.md) | [5.9](/filings/0001161697-26-000189.md) |
| Operating income | $m | [(1.8)](/filings/0001161697-24-000441.md) | [(2.2) d](/filings/0001161697-25-000103.md) | [(2.0)](/filings/0001161697-25-000169.md) | [(1.2)](/filings/0001161697-25-000217.md) | [(1.7)](/filings/0001161697-25-000372.md) | [(1.6) d](/filings/0001161697-26-000052.md) | [(1.2)](/filings/0001161697-26-000108.md) | [(0.3)](/filings/0001161697-26-000189.md) | [(0.9)](/filings/0001161697-25-000372.md) | [(0.5) d](/filings/0001161697-26-000052.md) | [(0.9)](/filings/0001161697-26-000108.md) | [0.6](/filings/0001161697-26-000189.md) |
| Interest expense | $m | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported |
| Income tax | $m | [(0.3)](/filings/0001161697-24-000441.md) | [5.4 d](/filings/0001161697-25-000103.md) | not reported | not reported | not reported | not reported | not reported | [0.0](/filings/0001161697-26-000189.md) | [(0.0)](/filings/0001161697-25-000372.md) | [0.0 d](/filings/0001161697-26-000052.md) | not reported | [0.0](/filings/0001161697-26-000189.md) |
| Net income | $m | [(1.4)](/filings/0001161697-24-000441.md) | [(7.5) d](/filings/0001161697-25-000103.md) | [(1.9)](/filings/0001161697-25-000372.md) | [(1.0)](/filings/0001161697-25-000372.md) | [(1.6)](/filings/0001161697-25-000372.md) | [(1.6) d](/filings/0001161697-26-000052.md) | [(1.2)](/filings/0001161697-26-000189.md) | [(0.2)](/filings/0001161697-26-000189.md) | [(0.8)](/filings/0001161697-25-000372.md) | [(0.5) d](/filings/0001161697-26-000052.md) | [(0.8)](/filings/0001161697-26-000189.md) | [0.3](/filings/0001161697-26-000189.md) |
| Diluted EPS | $ per share | [(0.03)](/filings/0001161697-24-000441.md) | not reported | [0.04](/filings/0001161697-25-000169.md) | [0.02](/filings/0001161697-25-000217.md) | [0.03](/filings/0001161697-25-000372.md) | not reported | [(0.03)](/filings/0001161697-26-000108.md) | [0.00](/filings/0001161697-26-000189.md) | [0.02](/filings/0001161697-25-000372.md) | not reported | [(0.02)](/filings/0001161697-26-000108.md) | [0.01](/filings/0001161697-26-000189.md) |
| Basic EPS | $ per share | [(0.03)](/filings/0001161697-24-000441.md) | not reported | [0.04](/filings/0001161697-25-000169.md) | [(0.02)](/filings/0001161697-24-000334.md) | [(0.03)](/filings/0001161697-24-000441.md) | not reported | [(0.03)](/filings/0001161697-26-000108.md) | [0.00](/filings/0001161697-26-000189.md) | not reported | not reported | [(0.02)](/filings/0001161697-26-000108.md) | [0.01](/filings/0001161697-26-000189.md) |

- Revenue: us-gaap:Revenues
- Cost of revenue: us-gaap:CostOfGoodsAndServicesSold
- Gross profit: us-gaap:GrossProfit
- Research and development: us-gaap:ResearchAndDevelopmentExpense
- Selling, general and administrative: us-gaap:SellingGeneralAndAdministrativeExpense
- Operating income: us-gaap:OperatingIncomeLoss
- Interest expense: not reported
- Income tax: us-gaap:IncomeTaxExpenseBenefit
- Net income: us-gaap:NetIncomeLoss
- Diluted EPS: us-gaap:EarningsPerShareDiluted
- Basic EPS: us-gaap:EarningsPerShareBasic

## Balance sheet

| Line item | Unit | Q3 FY2023 (2023-09-30) | FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Cash and equivalents | $m | [10.8](/filings/0001161697-23-000568.md) | [11.5](/filings/0001161697-25-000103.md) | [10.8](/filings/0001161697-24-000226.md) | [10.5](/filings/0001161697-24-000334.md) | [8.8](/filings/0001161697-24-000441.md) | [9.6](/filings/0001161697-26-000052.md) | [8.7](/filings/0001161697-25-000169.md) | [8.1](/filings/0001161697-25-000217.md) | [8.5](/filings/0001161697-25-000372.md) | [8.9](/filings/0001161697-26-000189.md) | [8.8](/filings/0001161697-26-000108.md) | [8.3](/filings/0001161697-26-000189.md) |
| Current assets | $m | [21.7](/filings/0001161697-23-000568.md) | [20.3](/filings/0001161697-25-000103.md) | [19.5](/filings/0001161697-24-000226.md) | [19.4](/filings/0001161697-24-000334.md) | [18.9](/filings/0001161697-24-000441.md) | [19.1](/filings/0001161697-26-000052.md) | [19.0](/filings/0001161697-25-000169.md) | [17.6](/filings/0001161697-25-000217.md) | [19.4](/filings/0001161697-25-000372.md) | [20.0](/filings/0001161697-26-000189.md) | [20.6](/filings/0001161697-26-000108.md) | [19.5](/filings/0001161697-26-000189.md) |
| Total assets | $m | [35.4](/filings/0001161697-23-000568.md) | [28.5](/filings/0001161697-25-000103.md) | [27.5](/filings/0001161697-24-000226.md) | [27.3](/filings/0001161697-24-000334.md) | [27.4](/filings/0001161697-24-000441.md) | [27.2](/filings/0001161697-26-000052.md) | [27.2](/filings/0001161697-25-000169.md) | [25.5](/filings/0001161697-25-000217.md) | [27.1](/filings/0001161697-25-000372.md) | [28.2](/filings/0001161697-26-000189.md) | [28.6](/filings/0001161697-26-000108.md) | [28.0](/filings/0001161697-26-000189.md) |
| Current liabilities | $m | [4.2](/filings/0001161697-23-000568.md) | [4.5](/filings/0001161697-25-000103.md) | [4.9](/filings/0001161697-24-000226.md) | [5.1](/filings/0001161697-24-000334.md) | [6.3](/filings/0001161697-24-000441.md) | [7.2](/filings/0001161697-26-000052.md) | [7.8](/filings/0001161697-25-000169.md) | [6.1](/filings/0001161697-25-000217.md) | [7.8](/filings/0001161697-25-000372.md) | [8.2](/filings/0001161697-26-000189.md) | [8.9](/filings/0001161697-26-000108.md) | [7.2](/filings/0001161697-26-000189.md) |
| Total liabilities | $m | [7.9](/filings/0001161697-23-000568.md) | [8.1](/filings/0001161697-25-000103.md) | [8.4](/filings/0001161697-24-000226.md) | [8.6](/filings/0001161697-24-000334.md) | [9.7](/filings/0001161697-24-000441.md) | [10.4](/filings/0001161697-26-000052.md) | [10.9](/filings/0001161697-25-000169.md) | [9.0](/filings/0001161697-25-000217.md) | [10.6](/filings/0001161697-25-000372.md) | [11.2](/filings/0001161697-26-000189.md) | [11.7](/filings/0001161697-26-000108.md) | [9.9](/filings/0001161697-26-000189.md) |
| Long-term debt | $m | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported |
| Current portion of debt | $m | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported |
| Shareholders' equity | $m | [27.4](/filings/0001161697-24-000441.md) | [20.4](/filings/0001161697-26-000052.md) | [19.1](/filings/0001161697-25-000372.md) | [18.7](/filings/0001161697-25-000372.md) | [17.7](/filings/0001161697-25-000372.md) | [16.8](/filings/0001161697-26-000189.md) | [16.3](/filings/0001161697-26-000189.md) | [16.5](/filings/0001161697-26-000189.md) | [16.5](/filings/0001161697-25-000372.md) | [17.0](/filings/0001161697-26-000189.md) | [16.9](/filings/0001161697-26-000189.md) | [18.1](/filings/0001161697-26-000189.md) |

- Cash and equivalents: us-gaap:CashAndCashEquivalentsAtCarryingValue
- Current assets: us-gaap:AssetsCurrent
- Total assets: us-gaap:Assets
- Current liabilities: us-gaap:LiabilitiesCurrent
- Total liabilities: us-gaap:Liabilities
- Long-term debt: not reported
- Current portion of debt: not reported
- Shareholders' equity: us-gaap:StockholdersEquity

## Cash flow

| Line item | Unit | Q3 FY2023 (2023-09-30) | Q4 FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Operating cash flow | $k | [(1,175) d](/filings/0001161697-24-000441.md) | [1,097 d](/filings/0001161697-25-000103.md) | [(347)](/filings/0001161697-25-000169.md) | [11.3 d](/filings/0001161697-25-000217.md) | [(924) d](/filings/0001161697-25-000372.md) | [940 d](/filings/0001161697-26-000052.md) | [(237)](/filings/0001161697-26-000108.md) | [(460) d](/filings/0001161697-26-000189.md) | [65.5 d](/filings/0001161697-25-000372.md) | [1,095 d](/filings/0001161697-26-000052.md) | [14.7](/filings/0001161697-26-000108.md) | [216 d](/filings/0001161697-26-000189.md) |
| Capital expenditure | $k | [212 d](/filings/0001161697-24-000441.md) | [196 d](/filings/0001161697-25-000103.md) | [133](/filings/0001161697-25-000169.md) | [124 d](/filings/0001161697-25-000217.md) | [1,084 d](/filings/0001161697-25-000372.md) | [(43.6) d](/filings/0001161697-26-000052.md) | [443](/filings/0001161697-26-000108.md) | [28.8 d](/filings/0001161697-26-000189.md) | [52.5 d](/filings/0001161697-25-000372.md) | [408 d](/filings/0001161697-26-000052.md) | [46.2](/filings/0001161697-26-000108.md) | [108 d](/filings/0001161697-26-000189.md) |
| Share repurchases | $k | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported |

- Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities
- Capital expenditure: us-gaap:PaymentsToAcquireProductiveAssets
- Share repurchases: not reported

## Shares

| Line item | Unit | Q3 FY2022 (2022-09-30) | Q1 FY2023 (2023-03-31) | Q2 FY2023 (2023-06-30) | Q3 FY2023 (2023-09-30) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Diluted shares (weighted) | millions of shares | [45.0](/filings/0001161697-23-000568.md) | [45.5](/filings/0001161697-24-000226.md) | [45.6](/filings/0001161697-24-000334.md) | [45.6](/filings/0001161697-24-000441.md) | [45.7](/filings/0001161697-25-000169.md) | [45.8](/filings/0001161697-25-000217.md) | [45.9](/filings/0001161697-25-000372.md) | [46.0](/filings/0001161697-26-000108.md) | [46.2](/filings/0001161697-26-000189.md) | [46.2](/filings/0001161697-25-000372.md) | [46.4](/filings/0001161697-26-000108.md) | [49.5](/filings/0001161697-26-000189.md) |

- Diluted shares (weighted): us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding

Shares outstanding: 46,171,902 at 2026-08-05, from the cover of the [10-Q filed 2026-08-05](/filings/0001161697-26-000189.md) (dei:EntityCommonStockSharesOutstanding).

Source: SEC EDGAR, XBRL company facts. Last ingested by Listed: Oct 24, 2026, 15:22 ET. No prices; not investment advice.